Catalyst Dossier · compiled by CeliA 🧫
Eisai (ESALY)
Healthcare · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-01 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Not yet
generate it
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
The catalyst path
- 2026-11-01 (est.)Phase 2 · Lenvatinibimp 7/10
- 2026-12-03 (est.)Phase 2 · Lecanemabimp 7/10
- 2026-12-15 (est.)Phase 2 · Lenvatinibimp 7/10
- 2027-01-15 (est.)Phase 2 · Lenvatinib + Letrozoleimp 7/10
- 2027-02-14 (est.)Phase 2 · E2086imp 7/10
- 2027-03-31 (est.)Phase 2 · E7389-LFimp 7/10
- 2027-04-06 (est.)Phase 2 · Perampanel Oral Suspensionimp 7/10
- 2027-04-15 (est.)Phase 2 · Lenvatinibimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| E7389-LF | Phase 2 | Solid Neoplasms |
| Teprenone | Phase 3 | Gastric or Duodenal Ulcers Caused by Low-dose Aspirin |
| T-614 | Phase 3 | Rheumatoid Arthritis |
| Eszopiclone 1 mg | Phase 3 | Primary Insomnia |
| E7080 capsule | Phase 2 | Thyroid Cancer |
| Eperisone hydrochloride and Diclofenac sodium | Phase 3 | Acute Musculoskeletal Spasm Due to Low Back Pain |
| Clevudine | Phase 3 | Chronic Hepatitis B |
| Eszopiclone 1 mg- Elderly | Phase 3 | Insomnia |
| BOTULINUM TOXIN TYPE B | Phase 2 | Cervical Dystonia |
| methylcobalamin | Phase 3 | Amyotrophic Lateral Sclerosis |
| E7777 | Phase 2 | Peripheral T-cell Lymphoma |
| Rabeprazole sodium, 5 mg Tablets | Phase 2 | Healthy |
| E7090 | Phase 2 | Cholangiocarcinoma |
| E5555 50 mg | Phase 2 | Coronary Artery Disease |
| E7389 (Eribulin Mesylate) | Phase 3 | HER2-Negative Breast Cancer |
| menatetranone | Phase 3 | Postmenopausal Osteoporosis |
| Tazemetostat | Phase 2 | Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma |
| Dotinurad | Phase 3 | Gout |
| E6742 | Phase 2 | Lupus Erythematosus, Systemic |
| Lorcaserin 10 mg twice a day (BID) | Phase 3 | Obesity |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ESALY (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.